Fapon Biopharma Launches First-in-Class FP008 Immunotherapy for Solid Tumours
Fapon Biopharma has introduced FP008 as a pioneering immunotherapy designed for patients with solid tumours that are resistant to anti-PD-1 treatment, addressing a critical unmet medical need in oncology.
FP008 is a novel anti-PD-1×IL-10M fusion protein designed to enhance immune response while minimising haematological toxicity. The engineered IL-10 monomer (IL-10M) reduces side effects, while the anti-PD-1 antibody strengthens IL-10M activity by targeting PD-1 and promoting activation.
Solid tumours that fail to respond to anti-PD-1 therapy often exhibit immune exhaustion, particularly among CD8(+) T cells.
Preclinical studies by Fapon Biopharma have demonstrated that FP008 can counteract this process by limiting terminal exhaustion of these cells and improving their ability to produce key immune molecules, including IFN-γ and GZMB.
In mouse models, FP008 significantly increased CD8(+) T-cell infiltration within tumours and exhibited strong anti-tumour activity. Safety and pharmacokinetic studies in cynomolgus monkeys further support its potential for clinical development.
FP008 represents a promising new treatment for patients with limited therapeutic options and may contribute to advances in solid tumour treatment.
